Zomedica Pharmaceuticals Corp. Closes $20 Million Public Offering

ANN ARBOR, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (a??Zomedicaa?? or the a??Companya??), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant.
H.C. Wainwright & Co. acted as exclusive placement agent for the offering.The gross proceeds from this offering are approximately $20.0 million, before deducting placement agenta??s fees and other estimated offering expenses payable by the Company, assuming none of the warrants sold in this offering are exercised for cash.A Zomedica intends to use the net proceeds from this offering for the continued development of its TRUFORMATM diagnostic platform, including making milestone payments, as they come due, under its existing license and collaboration agreements, and other general corporate and working capital purposes.The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-238322) previously filed with and declared effective by the Securities and Exchange Commission (the a??SECa??) on May 26, 2020.A  A final prospectus relating to the securities being offered was filed with the SEC on May 27, 2020 and is available on the SECa??s website at Electronic copies of the final prospectus relating to the offering may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by calling (646) 975-6996 or by emailing or at the SECa??s website at
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Июль 2020    »